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For more than thirty years, proteases
have been known to be critically involved
in a number of steps in tumor progres-
sion, such as tumor growth, invasion,
migration and metastasis (Koblinski et al.,
2000). Although ?500–600 proteases
have been found to exist in human and
mouse genomes (Puente et al., 2003),
not all of them have been found to be
linked with cancer. The main stage has
been primarily reserved for the
metalloproteases from the MMP family
(matrix metalloproteases) and, to a
smaller extent, to the serine protease
uPA (urokinase-type plasminogen activa-
tor). Although evidence for their involve-
ment in cancer progression has been
accumulating for more than two decades,
cysteine cathepsins have always some-
how lagged behind (Rao et al., 2003;
Koblinski et al., 2000; Kos and Lah,
1998). However, the failure of broad-
spectrum MMP inhibitors in clinical
trials (Coussens et al., 2002) has
opened the door for other proteases
to be considered as relevant drug
targets in anticancer therapies.
In this issue of Cancer Cell,
Joyce et al. (2004) present data
showing that increased cysteine
cathepsin levels and activities in
tumors are associated with the
angiogenic vasculature and invasive
fronts of pancreatic neuroendocrine
carcinomas in the RIP1-Tag2 trans-
genic mouse model, accompanied
by differential expression of cathep-
sins in immune and endothelial
cells. Support for the generality of
these findings comes from a pilot
study in a second mouse model,
mimicking human cervical carcino-
genesis (K14-HPV/E2). These are
the first transgenic mouse models of
cancer in which cathepsins have
been studied, and they offer a major
advantage over cell culture and
xenograft models. Moreover, trans-
genic mouse models offer the possi-
bility to study the full ontogeny of
cancer development, including the
early premalignant steps; by contrast,
xenotransplants and human clinical 
studies typically only involve the 
later stages, where the disease has
already advanced. However, genetically 
engineered mouse models cannot
necessarily be directly translated to
human disease, nor do we have mouse
models for all types of cancer, suggest-
ing that both old and new model systems
will continue to be instructive.
So how are cysteine cathepsins, nor-
mally involved in intracellular turnover,
immune response, protein processing,
and other important cellular processes,
connected to cancer? There are 11 cys-
teine cathepsins present in the human
genome (B, C, F, L, K, V, S, X/Z, H, W,
and O) and 19 in mouse (10 of them are
orthologs), each with different expres-
sion patterns, levels, and specificities, all
of which contribute to their differential
physiological roles. Some, such as
cathepsins B, L, and H, are very abun-
dant; none are completely specific, and
most are highly active but differently sta-
ble at neutral pH—collectively making
these proteases potentially harmful if
transposed outside of their normal
endosomal/lysosomal localization (Turk
et al., 2001). One situation where trouble
could occur is in the degradation of the
extracellular matrix (ECM), a proteolytic
event associated both with early tumor
development, affecting tumor cell prolif-
eration and angiogenesis, and with dis-
semination of malignant cells from
primary tumors. Although ECM degrada-
tion has largely been attributed to MMPs,
it is now clear that different classes of
proteases can also make a contribution,
with cathepsins being involved either
directly in the degradation of compo-
nents of ECM, such as laminin,
fibronectin, and collagen, or through
the modulation of protease-sensitive
regulatory networks, involving other
proteases as well as non-proteases,
such as annexin II, found at the cel-
lular surface of cancer cells
(Koblinski et al., 2000; Roshy et al.,
2003).
The common belief is that
cathepsin-mediated degradation of
the ECM is primarily extracellular at
the invasive front of tumor cells, also
observed by Joyce et al. (2004).
However, analyses of proteolytic
degradation of quenched fluorescent
protein substrates in living cells
showed that cells differ in their sites
of matrix remodeling, which can be
extracellular, intracellular, or even a
combination of both (Roshy et al.,
2003; Premzl et al., 2003).
Furthermore, inhibitors capable of
blocking both intra- and extracellular
fractions of cathepsin B were the
most effective in reducing the inva-
sive potential of tumor cells (Premzl
et al., 2003). It is thus the activity of a
protease, often connected with
altered cellular localization, that usu-
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Cysteine cathepsins are involved in degradation of extracellular matrix, facilitating growth, invasion, and metastasis of tumor
cells, in tumor angiogenesis, in apoptosis, and in events of inflammatory and immune responses. In this issue of Cancer Cell,
Joyce et al. (2004) demonstrate association of increased cathepsins activity with angiogenic vasculature and invasive fronts
of carcinomas during tumorigenesis in transgenic mouse models using activity-based chemical probes and in vivo imaging.
Moreover, this study shows that a broad-spectrum cysteine cathepsin inhibitor effectively blocks several stages of tumorige-
nesis in the RIP1-Tag2 transgenic mouse model, offering new therapeutic opportunities in cancer treatment.
Figure 1. Expression of cathepsin B in human invasive
ductal breast carcinoma
The carcinoma is on the right and normal tissue, includ-
ing tumor cell nests, is on the left. Cathepsin B (brown
color revealed by peroxidase staining) is located at
the invasive front of the tumor and involved in the
basement membrane degradation.
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ally makes the critical switch between
harmless and harmful, and not the differ-
ential expression pattern. That is precise-
ly one of the important points made by
Joyce et al. (2004) by using small cell
permeable active-site directed probes:
they were able to measure and image
protease activities in living cells, which is
becoming a key parameter of analysis in
cancer, and in other biological systems.
The involvement of cathepsins in
regulation of angiogenesis reveals yet
another distinct role for cathepsins in
tumor progression (Joyce et al., 2004),
adding to previous results of Felbor et al.
(2000) implicating cathepsin L in genera-
tion of the angiogenesis inhibitor endo-
statin, as well as to more recent data
suggesting a role for cathepsin S in
wound healing (Shi et al., 2003). Thus,
new functions of cathepsins in tumor pro-
gression are emerging, and we can
expect more to be revealed.
Despite differential expression of 6
cathepsins in the development of pan-
creatic islet carcinomas (Joyce et al.,
2004), their individual functions have not
yet been assigned. Nevertheless, these
alterations in cathepsin expression levels
(primarily of cathepsins B and L), pro-
cessing, and localization, which have
been observed in various tumors
(breast, lung, brain, colon, and head and
neck tumors), when compared to their
normal and benign tissue counterparts,
have also made cysteine cathepsins
valuable prognostic and diagnostic
markers (Kos and Lah, 1998).
An important breakthrough achieved
by Joyce et al. (2004) was the use of an
analog of the irreversible cathepsin bind-
ing scaffold E-64 as a broad spectrum
pharmacological inhibitor of cysteine
cathepsins. This compound, JPM-OEt,
had profound effects on tumor growth,
invasiveness, and angiogenic switching,
disrupting both early and late stages of
tumorigenesis, in contrast to MMP
inhibitors, which have not proved effec-
tive in the later stages of the disease
(Coussens et al., 2002). Interestingly, the
cathepsin inhibitor was not found to be
toxic at the dosage used, which led the
authors to suggest its potential use in
cancer treatment. Despite these promis-
ing results (Joyce et al., 2004), one
should be very careful when suggesting
use of nonselective inhibitors in treat-
ment of a disease such as cancer, where
the roles of individual players, e.g., cys-
teine cathepsins, are not fully resolved.
Recall the failed clinical trials targeting
late stage tumors with broad-spectrum
MMP inhibitors, which showed beneficial
effects in mouse models (Coussens et
al., 2002), albeit at earlier stages.
A number of other proteases, such
as proteasome and histone deacety-
lases, are emerging as potential drug
targets in cancer, and new selective
inhibitors of MMPs are being developed.
Another interesting approach in anti-
cancer therapy is based on protease
activation of apoptosis (Schimmer et al.,
2004). Instead of blocking protease
activity, they suppressed the activity of
XIAP, an endogenous inhibitor of another
family of cysteine proteases, the caspas-
es, thereby enabling caspase activation,
selectively sensitizing a number of differ-
ent cancer cells to chemotherapeutic
drugs or even directly inducing cancer
cell apoptosis.
Future research should reveal which
of the protease-based approaches will
be the most beneficial for targeting differ-
ent forms of cancer. Given the variety of
cancers, with distinctive molecular and
cellular anatomy, there is not likely to be
one ideal therapy for all of them. Specific
protease inhibitors, likely in combination
with conventional anticancer agents, will
probably prove to have value for certain
forms of cancer. It is now becoming clear
that cysteine cathepsins should be seri-
ously considered as potential targets in
cancer treatment.
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